Presentation of Kancera’s Interim Report for the first quarter 2024
Presentation of Kancera’s Interim Report for the fourth quarter 2023
Presentation of the statistical analyses of the FRACTAL top line results
CEO Peter Selin presents Kancera’s Q3 2023 Interim Report
CEO Peter Selin presents KANDOVA, Kancera’s ongoing clinical study in ovarian cancer
The website uses cookies. By clicking on "Accept all", you agree to the use of all cookies. However, you have the opportunity, by clicking "Settings cookies", to give a controlled consent. Read More
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.